Phase II, Dose-ranging Study to Evaluate the Efficacy Dose Response and Pharmacokinetics of Intravenous Atorvastatin in Hypercholesterolemic Patients Previously Controlled With Oral Atorvastatin
Phase of Trial: Phase II
Latest Information Update: 16 Dec 2018
At a glance
- Drugs Atorvastatin (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Cumberland Pharmaceuticals
- 30 Nov 2018 Planned End Date changed from 1 Jan 2019 to 1 Mar 2019.
- 30 Nov 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Mar 2019.
- 14 Aug 2018 Status changed from not yet recruiting to recruiting.